Bill
HD 3177
Authorizes collaborative drug therapy management (CDTM) in ambulatory clinics with physician and pharmacist supervision and medical staff approval.
Overview
- Purpose: To authorize and regulate collaborative drug therapy management (CDTM) within ambulatory care clinics, with appropriate physician and pharmacist supervision and clinic governance oversight. The bill seeks to optimize CDTM practices by creating a clear eligibility framework and requiring medical staff approval.
- Bill status: Proposed bill. Introduced in the 2025-2026 session (House Docket No. 3177). It appears as a companion or similar measure to a prior filing (House No. 2134 of 2023-2024).
What the bill would do
- Allow CDTM in ambulatory care clinics licensed under Chapter 111, Section 51, regardless of conflicting general or special laws, provided two conditions are met:
1. On-site or off-site supervision by both the attending physician and a collaborating pharmacist.
2. Approval of CDTM by the ambulatory care clinic’s medical staff executive committee (or designee) or by the medical director (or designee).
- The bill uses a “Notwithstanding” clause, meaning it would override existing language in Section 24 B1/2 of Chapter 112 and any other laws that might restrict CDTM in these settings.
Key provisions and requirements
- Scope: Applies specifically to ambulatory care clinics licensed under Chapter 111, Section 51.
- Supervisory requirement: CDTM activities must be supervised by both an attending physician and a collaborating pharmacist (on-site or off-site).
- Governance/approval: CDTM must be approved by the clinic’s medical staff executive committee or a designee, or by the medical director or designee.
- Legal effect: The bill amends the General Laws to permit CDTM in these clinics notwithstanding any contrary provisions in other laws.
Who would be affected
- Ambulatory care clinics licensed under Chapter 111, Section 51.
- Attending physicians participating in CDTM.
- Collaborating pharmacists involved in CDTM.
- Clinic leadership (medical staff executive committees, medical directors) responsible for approving CDTM arrangements.
- Patients receiving CDTM in participating ambulatory care clinics, who may benefit from expanded pharmacist-physician collaborative care.
Procedural and timeline notes
- Introduction: The bill is listed as introduced in the 2025-2026 session (HD 3177). There is a note indicating a similar matter previously filed in 2023-2024 (House No. 2134).
- Effective date: The text provided does not specify an explicit effective date; standard practice would be “upon enactment” (signature into law) unless otherwise detailed in later amendments.
- Relationship to existing law: Uses a Notwithstanding clause to supersede potential countervailing provisions, situating CDTM within ambulatory clinics as a prioritized regulatory framework.
Impact considerations
- Potential benefits: Broader access to CDTM, more integrated pharmacotherapy management, and potential improvements in chronic disease outcomes and medication safety in ambulatory settings.
- Implementation considerations: Clinics would need to establish governance processes for approving CDTM, ensure supervisory arrangements with physicians and pharmacists, and align with any regulatory or payer requirements for reimbursement and scope of practice.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
